Movement Alert｜LEADS BIOLABS-B Falls 5.6% in Regular Trading, Biotech Sector Weakness Compounds Post-Volatility Profit-Taking

Market Focus09:48

On September 24, LEADS BIOLABS-B fell 5.6% in regular trading, trading at HK$53.2/share, with turnover of HK$25.81 million.

The decline came amid broad weakness across the biotechnology sector. Within the sector, AKESO fell 3.23%, REMEGEN fell 4.63%, EVEREST MED fell 3.86%, INNOVENT BIO fell 2.51%, and BEONE MEDICINES fell 1.1%, reflecting subdued sector sentiment.

At the individual stock level, LEADS BIOLABS-B has experienced sharp swings in recent sessions — dropping 5.59% on September 22 following disclosure that its employee incentive platform Nanjing Lizhi sold approximately 859,100 shares at an average price of HK$63.69, then rebounding 5.54% on September 23 as markets digested the selection of its pivotal Phase IIb EP-NEC study as a Late-Breaking Abstract at ESMO 2026. The renewed selling pressure suggests short-term profit-taking continues. Additionally, the company reported an interim net loss of approximately RMB 222 million, widening 33.38% year-over-year, underscoring that fundamentals remain in a loss-making phase.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103639728?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-24 09:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103639728","market":"us","top_or_hot":-1,"title":"Movement Alert｜LEADS BIOLABS-B Falls 5.6% in Regular Trading, Biotech Sector Weakness Compounds Post-Volatility Profit-Taking","media":"Market Focus","content":"<p><p>On September 24, LEADS BIOLABS-B fell 5.6% in regular trading, trading at HK$53.2/share, with turnover of HK$25.81 million.</p><p>The decline came amid broad weakness across the biotechnology sector. Within the sector, AKESO fell 3.23%, REMEGEN fell 4.63%, EVEREST MED fell 3.86%, INNOVENT BIO fell 2.51%, and BEONE MEDICINES fell 1.1%, reflecting subdued sector sentiment.</p><p>At the individual stock level, LEADS BIOLABS-B has experienced sharp swings in recent sessions — dropping 5.59% on September 22 following disclosure that its employee incentive platform Nanjing Lizhi sold approximately 859,100 shares at an average price of HK$63.69, then rebounding 5.54% on September 23 as markets digested the selection of its pivotal Phase IIb EP-NEC study as a Late-Breaking Abstract at ESMO 2026. The renewed selling pressure suggests short-term profit-taking continues. Additionally, the company reported an interim net loss of approximately RMB 222 million, widening 33.38% year-over-year, underscoring that fundamentals remain in a loss-making phase.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜LEADS BIOLABS-B Falls 5.6% in Regular Trading, Biotech Sector Weakness Compounds Post-Volatility Profit-Taking</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜LEADS BIOLABS-B Falls 5.6% in Regular Trading, Biotech Sector Weakness Compounds Post-Volatility Profit-Taking\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-24 09:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 24, LEADS BIOLABS-B fell 5.6% in regular trading, trading at HK$53.2/share, with turnover of HK$25.81 million.</p><p>The decline came amid broad weakness across the biotechnology sector. Within the sector, AKESO fell 3.23%, REMEGEN fell 4.63%, EVEREST MED fell 3.86%, INNOVENT BIO fell 2.51%, and BEONE MEDICINES fell 1.1%, reflecting subdued sector sentiment.</p><p>At the individual stock level, LEADS BIOLABS-B has experienced sharp swings in recent sessions — dropping 5.59% on September 22 following disclosure that its employee incentive platform Nanjing Lizhi sold approximately 859,100 shares at an average price of HK$63.69, then rebounding 5.54% on September 23 as markets digested the selection of its pivotal Phase IIb EP-NEC study as a Late-Breaking Abstract at ESMO 2026. The renewed selling pressure suggests short-term profit-taking continues. Additionally, the company reported an interim net loss of approximately RMB 222 million, widening 33.38% year-over-year, underscoring that fundamentals remain in a loss-making phase.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1103639728","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103639728","pubTimestamp":1790214529,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 24, LEADS BIOLABS-B fell 5.6% in regular trading, trading at HK$53.2/share, with turnover of HK$25.81 million.The decline came amid broad weakness across the biotechnology sector. Within...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09887":"维立志博-B"},"translate_title":"走势警报|LEADS BIOLABS-B 常规交易中下跌 5.6%，生物技术板块疲软加剧波动后获利了结","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"On September 24, LEADS BIOLABS-B fell 5.6% in regular trading, trading at HK$53.2/share, with turnover of HK$25.81 million.The decline came amid broad weakness across the biotechnology sector. Within the sector, AKESO fell 3.23%, REMEGEN fell 4.63%, EVEREST MED fell 3.86%, INNOVENT BIO fell 2.51%, and BEONE MEDICINES fell 1.1%, reflecting subdued sector sentiment.At the individual stock level, LEADS BIOLABS-B has experienced sharp swings in recent sessions — dropping 5.59% on September 22 following disclosure that its employee incentive platform Nanjing Lizhi sold approximately 859,100 shares at an average price of HK$63.69, then rebounding 5.54% on September 23 as markets digested the selection of its pivotal Phase IIb EP-NEC study as a Late-Breaking Abstract at ESMO 2026. The renewed selling pressure suggests short-term profit-taking continues. Additionally, the company reported an interim net loss of approximately RMB 222 million, widening 33.38% year-over-year, underscoring that fundamentals remain in a loss-making phase.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103639728","isCrawlerRequest":true}